Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 128, Issue 3, Pages 1057-1073Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI96329
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81788101, 81661128007, 81530080, 81773062]
- National Natural Science Fund for Young Scholars of China [81502473]
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine [2016-I2M-1-007]
Ask authors/readers for more resources
Dynamic interaction with the immune system profoundly regulates tumor cell dormancy. However, it is unclear how immunological cues trigger cancer cell-intrinsic signaling pathways for entering into dormancy. Here, we show that IFN-beta treatment induced tumor-repopulating cells (TRC) to enter dormancy through an indolamine 2,3-dioxygenase/kynurenine/aryl hydrocarbon receptor/p27-dependent (IDO/Kyn/AhR/p27-dependent) pathway. Strategies to block this metabolic circuitry did not relieve dormancy, but led to apoptosis of dormant TRCs in murine and human melanoma models. Specifically, blocking AhR redirected IFN-beta signaling to STAT3 phosphorylation through both tyrosine and serine sites, which subsequently facilitated STAT3 nuclear translocation and subsequent binding to the p53 promoter in the nucleus. Upregulation of p53 in turn disrupted the pentose phosphate pathway, leading to excessive ROS production and dormant TRC death. Additionally, in melanoma patients, high expression of IFN-beta correlated with tumor cell dormancy. Identification of this mechanism for controlling TRC dormancy by IFN-beta provides deeper insights into cancer-immune interaction and potential new cancer immunotherapeutic modalities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available